Healthcare professionals' perspectives on expanding newborn genomic screening in the emirate of Abu Dhabi, United Arab Emirates: insights from a cross-sectional study Authors: Aminu S. Abdullahi, Y. M. Abu Alqumboz, Ahmed Jamal Bek, Mohammed Shaidul, Maryam Alktifan, Fatma Alhammadi, Alia Rashed Manea Alshamsi, Meera Saeed Nhayah Alkaabi, Marwa Alkatheeri, Taif AlEissaee, Mohammad Alsaadi, Mohammedfaeq Alqolaq, Omar Alzaabi, Khalid Almaamari, Nasser Abdulla Alshamsi, Saoud AlTamimi, Khalifa Alseiari, Ahmed AlQedra, Mohamed Salem Alameri, Azhar T. Rahma Published: 2026 ABSTRACT BackgroundGenomic Newborn Screening (gNBS) could transform neonatal healthcare by enabling early detection of genetic disorders, timely intervention, and improved health outcomes. This study assessed healthcare professionals' self-reported knowledge, attitudes, and challenges regarding expanded newborn genomic screening in Abu Dhabi, United Arab Emirates (UAE), and identified factors influencing its integration into neonatal healthcare.MethodsA cross-sectional survey was distributed to healthcare professionals across public and private facilities in Abu Dhabi, using random and snowball sampling. Data were analyzed using descriptive statistics, chi-square tests, and logistic regression to examine associations between gNBS self-reported knowledge, attitudes, and professional characteristics.ResultsAbout 46% (95% CI: 40%−52%) of professionals demonstrated good self-reported knowledge of gNBS, with significantly higher awareness among those experienced in newborn screening and tandem mass spectrometry. While 70% supported expanding gNBS, key barriers included cost, lack of screening guidelines, and ethical concerns such as genetic privacy and psychological distress for families. Most participants (85%) supported upskilling nurses and midwives for cord blood collection. Additionally, severe combined immunodeficiency (SCID), Duchenne muscular dystrophy (DMD), and spinal muscular atrophy (SMA) were essential conditions for inclusion in expanded gNBS programs.ConclusionHealthcare professionals in Abu Dhabi recognize the potential of gNBS but also acknowledge key implementation challenges. Advancing implementation requires training, policy development, and ethical considerations. Future efforts should prioritize cost-effectiveness evaluations, regulatory frameworks, and stakeholder engagement to support sustainable and equitable gNBS implementation in the UAE. Introduction Newborn screening is a modern public health capability, allowing early detection of congenital and metabolic disorders, which can lead to health complications, delayed developmental milestones, or even mortality if ignored. By enabling early identification of at-risk infants, Newborn Screening (NBS) Programs have significantly reduced infant morbidity and mortality, improved health outcomes, and lessened the burden on healthcare systems (1, 2). The global newborn screening market is expected to grow at a 9.86% compound annual growth rate (CAGR) from $1.24 billion in 2023 to $2.16 billion by 2029, driven by government support, increased awareness, and technological advancements (3). Genomic Newborn Screening (gNBS), tandem mass spectrometry, and advanced DNA testing enhance the sensitivity and specificity of screening tests, enabling earlier and more accurate detection of genetic and metabolic abnormalities (4, 5). This paper shows how the UAE-Abu Dhabi is leading the way in newborn screening in the Middle East and North Africa (MENA) region, demonstrating its commitment to improving newborn health and reducing preventable diseases (6, 7); however, the effectiveness and delivery of these initiatives depend on healthcare professionals' implementation, promotion, and sustainability. Several international initiatives have evaluated gNBS, including the BabySeq Project in the United States, population-based genomic pilot programs in Belgium, and implementation efforts within the United Kingdom National Health Service (5, 8–12). These studies have demonstrated the clinical utility of early genomic detection while also highlighting ethical, economic, and health-system challenges associated with scaling gNBS into routine care. The UAE launched its National Neonatal Screening Program (NBS) in 1995, which covers over 40 disorders, including metabolic, endocrine, and genetic conditions such as phenylketonuria (PKU), congenital hypothyroidism, and sickle-cell disease (6). The program aims to prevent early health complications, improve neonatal outcomes, reduce diagnostic odyssey, and create a genetic disease database (13). However, barriers to its widespread implementation include a lack of awareness regarding the screening process, poor training, operational challenges to service delivery (14, 15), and inequalities in access to resources and healthcare infrastructure (16, 17). Therefore, understanding these issues is crucial for NBS's effectiveness. The study investigates Abu Dhabi practitioners' attitudes, self-reported knowledge, and obstacles toward the expanded newborn screening program, offering valuable insights for policymakers, healthcare administrators, and practitioners. It highlights professional experiences, training, implementation, and policy support gaps, contributing to the global discourse on newborn screening, improved health outcomes, and the long-term sustainability of NBS programs. Method The study employed a quantitative, cross-sectional design to assess healthcare professionals' self-reported knowledge, attitudes, and challenges regarding the expansion of gNBS in the UAE, using a piloted questionnaire distributed between June and January 2025, ensuring adequate time for participation. Study population The study targeted registered and active healthcare professionals in Abu Dhabi, including consultants, general practitioners, interns, residents, specialists, and allied healthcare professionals (including nurses, pharmacists, paramedics, and health educators), who were key stakeholders in implementing and sustaining newborn genomic screening programs in public and private healthcare facilities. Sample size The sample size was calculated using the formula for cross-sectional studies: n = Z2(1–P)/d2, where Z = 1.96 for a 95% confidence interval, expected prevalence of good gNBSknowledge among healthcare professionals, P = 0.8 as reported by Abeje (1), and d = 0.05 (margin of error). This yielded a minimum required sample of 243 participants. Sampling strategy and data source The study utilized the Shafafiya Portal, a centralized healthcare registry maintained by the Department of Health (DOH) Abu Dhabi (https://www.doh.gov.ae/en/shafafiya), to identify and invite eligible healthcare professionals. The database provided information on clinician licenses, specialties, facility names, and employment status, allowing stratification by urban and rural Abu Dhabi and pediatric experience. To reduce potential selection bias, random sampling was combined with chain sampling (snowballing), promoting broad participation across professions, experience levels, and healthcare settings (public/private, urban/rural). A stratified recruitment strategy further ensured a balanced representation of healthcare provider categories. Recruitment and engagement A multi-tiered recruitment strategy, employing random selection sampling and chain sampling (snowballing). Healthcare facilities were contacted for approval to distribute the survey. On-site visits were conducted to explain study objectives, obtain institutional approval, and provide printed surveys. Some institutions used internal survey distribution, allowing their HR departments to distribute printed surveys or email survey links to staff, and the snowball sampling method encouraged on-the-spot completion. Additionally, institutional collaboration was employed to increase participation. Survey administration The survey was offered in two formats: online via institutional email lists, WhatsApp groups, and professional networks, or printed during site visits. It remained open for 6 months to accommodate busy healthcare schedules, especially during the summer break, when many professionals were unavailable. Survey instrument and measures The survey, piloted among 50 healthcare professionals, was developed by adapting items and domains from previously published surveys assessing healthcare professionals' self-reported knowledge and attitudes toward newborn/genetic screening and genomic testing, and from implementation literature describing common barriers (1, 2, 18, 19). The draft instrument was reviewed for relevance to the Abu Dhabi context and piloted among healthcare professionals to improve clarity and face validity before full deployment. The pilot sample included physicians (consultants, residents), nurses, and allied health professionals working in pediatric and neonatal settings. Feedback was obtained regarding clarity, wording, and relevance of items. Minor modifications were made to improve question clarity and reduce ambiguity, particularly in the knowledge and ethical concern sections. Demographic information Age, gender, professional role, work experience, institution type (government, private, clinic, etc.), work setting (urban vs. rural), and previous exposure to newborn screening technologies. Self-reported knowledge assessment Familiarity with gNBS, understanding of gNBS applications and benefits, awareness of current UAE newborn screening protocols, and self-reported knowledge of TMS screening. Responses were categorized as good self-reported knowledge (know a lot, know some), or limited self-reported knowledge (know a little, do not know). Attitudes toward newborn genomic screening Perceived necessity of gNBSin Abu Dhabi, interest in expanding genomic screening, concerns regarding NGS (including ethical issues, privacy concerns, psychological burden on families), opinions on screening criteria [including whole-genome sequencing (WGS) vs. next-generation sequencing panels], sequential vs. simultaneous screening with Tandem Mass Spectrometry (TMS). Barriers and challenges Financial barriers (cost concerns and insurance coverage), technical challenges (need for advanced training and interpretation skills), healthcare system readiness (capacity for integrating genetic counseling services), ethical considerations (parental consent and data security concerns), implementation and policy considerations (preferred newborn screening technologies, policy recommendations for expanding genomic screening, identification of key disorders for inclusion in an expanded gNBS program, perceived role of nurses and midwives in sample collection from cord blood). Ethical considerations The study was approved by the UAE University Social Science Ethics Committee (ERSC 2024_4422), informed consent was obtained, and ethical guidelines outlined in the Declaration of Helsinki were adhered to. Participant confidentiality and anonymity were ensured, with the option to withdraw at any time. Data were securely stored on SurveyMonkey and were accessible only to the Principal Investigator. Data analysis Data were analyzed using R software (version 4.4.1). Categorical variables were summarized with frequencies and percentages. The level of self-reported knowledge about newborn genomic screening was categorized into two: good (comprising “know a lot” and “know some”) and limited (comprising “know a little” and “I do not know”). Pearson's Chi-squared test was used to assess associations between self-reported knowledge levels and participant characteristics, followed by binary logistic regression to adjust for confounders. STROBE guidelines This study followed the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for cross-sectional studies, ensuring transparency and methodological rigor. Results Participant characteristics A total of 362 participants, mostly females (61%) and 42% aged 30 years and below, were included in the study (Table 1). More than half of the participants (58%) had bachelor's degrees; others had either a master's degree (22%), a PhD (9%), or other qualifications (10%). The participants worked at various professional levels, including residents (21%), specialists (17%), general practitioners (11%), consultants (9.0%), interns (7%), and other professional titles (35.6%), with most of them working in urban areas (87%). A sizable number (43%) had academic experience, while 83% worked in pediatrics. Slightly more than half (55%) had experience in newborn screening, with 74% having, at most, 5 years of experience. Only 30% had experience with TMS screening programs. Table 1Participants' demographics and occupational characteristics (N = 362).CharacteristicN (%)Age (years) ≤ 30127 (42%)31–3551 (17%)36–4049 (16%)41–4524 (8.0%)46–5018 (6.0%)> 5032 (11%)GenderFemale185 (61%)Male116 (39%)Educational level Bachelor176 (58%) Masters67 (22%) PhD27 (9.0%) Othera31 (10%)Worked in academia (Yes)128 (43%)Professional title Consultant27 (9.0%) General practitioner32 (11%) Intern21 (7.0%) Resident62 (21%) Specialist52 (17%) Otherb107 (35.6%)Worked with pediatric (Yes)251 (83%)Worked with newborn Screening (Yes)166 (55%)Years working with newborn Screening ≤ 5126 (74%)6–1025 (15%)11–2010 (5.8%)>2010 (5.8%)Work locationRural39 (13%)Urban262 (87%)Experience with the TMS screening programNo138 (46%)Yes90 (30%)I do not know73 (24%)a Medical student, fellowship, Board Certified, diploma. b Dental assistant, paramedic, nurse, medical student, assistant nurse, pharmacist, health educator, Allied health, Genetic Counselor, Fellow, Director of Medical Education. Participants' demographics and occupational characteristics (N = 362). a Medical student, fellowship, Board Certified, diploma. b Dental assistant, paramedic, nurse, medical student, assistant nurse, pharmacist, health educator, Allied health, Genetic Counselor, Fellow, Director of Medical Education. Self-reported knowledge of gNBS Overall, 46% (95% CI: 40%−52%) of the participants reported having good self-reported knowledge of gNBS. The proportions of those with good gNBS self-reported knowledge were higher among academics (57% vs. 38%, p = 0.002), those working in urban areas (50% vs. 20%, p = 0.001), those who worked with newborn screening (58% vs. 31%, p < 0.001), those who had experience with TMS screening programs (72% vs. 34%, p < 0.001), those who have a higher interest in gNBS (60% vs. 15%, p < 0.001), and those willing to advocate for gNBS (50% vs. 12%, p < 0.001) (Table 2). Moreover, the prevalence of good gNBS self-reported knowledge was highest among interns/residents (57%), followed by specialists/consultants (50%), and general practitioners (32%). However, gNBS self-reported knowledge was not significantly associated with age, gender, education level, pediatric experience, or duration of working in newborn screening (p > 0.05). Table 2Factors associated with self-reported knowledge of genomic newborn screening (gNBS).CharacteristicNGS knowledge levelGood knowledge (n = 133, 46%)Limited knowledge (n = 155, 54%)p-valueAge (years)0.178 ≤ 40106 (48%)113 (52%)> 4027 (39%)42 (61%)Gender0.104Female76 (42%)103 (58%)Male57 (52%)52 (48%)Educational level0.400Bachelor83 (49%)85 (51%)Postgraduate38 (43%)51 (57%)Other12 (39%)19 (61%)Worked in academia0.002No62 (38%)101 (62%)Yes71 (57%)54 (43%)Professional title0.043Trainees (interns/residents)47 (57%)35 (43%)General practitioner9 (32%)19 (68%)Specialists/consultants38 (50%)38 (50%)Other28 (39%)44 (61%)Worked with pediatric0.186No18 (37%)30 (63%)Yes115 (48%)125 (52%)Worked with newborn screening< 0.001No39 (31%)88 (69%)Yes94 (58%)67 (42%)Years working with newborn screening0.528 ≤ 563 (57%)48 (43%)>525 (63%)15 (37%)Work location0.001Rural8 (22%)29 (78%)Urban125 (50%)126 (50%)Experience with the TMS screening program< 0.001No44 (34%)85 (66%)Yes63 (72%)24 (28%)Interest in NGS< 0.001High120 (60%)80 (40%)Low13 (15%)75 (85%)Willingness to advocate for NGS< 0.001No3 (12%)21 (88%)Yes120 (50%)120 (50%)NGS: newborn genomic screening. Factors associated with self-reported knowledge of genomic newborn screening (gNBS). NGS: newborn genomic screening. A multivariable model found that experience with the TMS screening program and interest in gNBS were independently associated with gNBS self-reported knowledge level (Table 3). Those who had experience with the TMS screening program (OR = 2.92, 95% CI = 1.16–7.56, p = 0.024) and those with a higher interest in gNBS (OR = 10.3, 3.74–33.5, p < 0.001) were significantly more likely to have good self-reported knowledge of gNBS. Table 3Univariate and multivariable logistic regression analysis for factors associated with good knowledge of newborn genomic screening.CharacteristiccOR95% CIp-valueaOR95% CIp-valueWorked in academiaNo1.00—1.00—Yes2.141.34, 3.46 0.002 1.020.46, 2.22>0.900Professional titleTrainees (interns/residents)1.00—1.00—General practitioner0.350.14, 0.85 0.024 0.340.08, 1.400.140Specialists/consultants0.740.40, 1.390.4000.420.15, 1.140.094Other0.470.25, 0.90 0.023 0.530.17, 1.560.200Worked with newborn screeningNo1.00—1.00—Yes3.171.95, 5.21 < 0.001 2.290.96, 5.520.062Work locationRural1.00—1.00—Urban3.61.65, 8.71 0.002 2.140.62, 8.060.200Experience with the TMS screening programNo1.00—1.00—Yes5.072.83, 9.32 < 0.001 2.921.16, 7.56 0.024 Interest in NGSLow1.00—1.00—High8.654.64, 17.3 < 0.001 10.33.74, 33.5 < 0.001 Willingness to advocate for NGSNo1.00—1.00—Yes72.34, 30.2 0.002 4.971.05, 37.20.067NGS: newborn genomic screening. cOR: Crude odds ratio. aOR: Adjusted odds ratio. Bold values indicate statistically significant associations. Univariate and multivariable logistic regression analysis for factors associated with good knowledge of newborn genomic screening. NGS: newborn genomic screening. cOR: Crude odds ratio. aOR: Adjusted odds ratio. Bold values indicate statistically significant associations. Attitudes toward gNBS and ethical concerns The majority of participants have some interest in gNBS (Supplementary Figure 1), with specialists/consultants (75%), followed by general practitioners (64%), and trainees (61%). Many participants recommended including SCID (45%), SMA (44%), and DMD (40%) in the expanded gNBS program (Supplementary Figure 2). Many participants cited potential harm from misunderstanding and misinterpretation of genetic information (38%), privacy (36%), and the psychological burden of carrying information about adult morbidity risk (34%) as major ethical issues in gNBS (Supplementary Figure 3). Additional free-text responses highlighted concerns related to equity and access to testing, potential insurance discrimination based on genetic information, stigmatization of affected families, inclusivity in screening eligibility, and the ethical implications of false-negative results. Some believed that expanded gNBS is unsuitable due to its low popularity and high costs (28%), lack of uniformity in genetic diseases and pathogenic genes (20%), and ethical and privacy issues (17%), among others (Supplementary Figure 4). Most participants believed that gNBS offers significant advantages, including its ability to extend screening to diseases not suitable for biochemical analysis or that lack reliable biomarkers (39%), clarifying ambiguous results and guiding accurate medication (25%), and determining mutation sources at the molecular level (21%) (Supplementary Figure 5). PCR combined with next-generation sequencing panels (25%) and whole-genome sequencing (25%) were the most popular screening technologies among the participants. However, 30% of participants were unaware of these technologies (Supplementary Figure 6). Key factors for choosing screening technology included high throughput, large data volume, and accuracy (39%), cost and price (31%), simple operation, localization detection, and quality control (29%), and advanced technology (27%), among others (Supplementary Figure 7). The majority of respondents (42%) said all newborns and those with positive MS/MS screening results (29%) should undergo gNBS (Supplementary Figure 8). Resources needed for the clinical application of gNBS Regarding the resources needed for the clinical application of gNBS, 63% of participants mentioned knowledge of neonatal genetic diseases, such as diagnosis, treatment, and intervention. Other suggested resources included abilities in report interpretation and genetic counseling (40%), and policies, regulations, technical specifications, and expert consensus (36%) (Supplementary Figure 9). Furthermore, 85% of participants agreed that nurses and midwives should be upskilled in cord blood sample collection (Supplementary Figure 10). Table 4 presents participants' responses on the necessity of gNBS in Abu Dhabi, major concerns, screening principles, the application modes of NGS and TMS, capabilities improvement, the main reasons for promoting expanded gNBS, and reasonable prices for gNBS. Table 4Attitudes and perceptions toward NGS among participants (N = 362).Questions and responsesResponse, N (%)Do you think it is necessary to carry out NGS in Abu Dhabi?Very much necessary178 (61%)Somewhat necessary91 (31%)Unnecessary6 (2.1%)I do not know15 (5.2%)What is your biggest concern about NGS?As a screening technology, it is unsatisfactory in terms of popularity, reporting time, and high cost.31 (11%)Great challenge for clinical counseling ability because of too much genetic information.57 (20%)Lack of treatment interventions for screening diseases.70 (24%)Too much genetic information may cause ethical, counseling, and psychological burden problems.96 (33%)I do not know35 (12%)What is your view about the principles for screening disease types, pathogenic genes, and mutations?Both complement each other, and Tandem Mass Spectrometry (MS/MS) screening cannot be completely replaced.63 (23%)Including at least 90% of the diseases by Tandem Mass Spectrometry (MS/MS) screening.9 (3.3%)It only includes pathogenic and like pathogenic mutations, while excluding Variants of Uncertain Significance (VUS).11 (4.0%)Some serious genetic diseases have high incidence and can be intervened or treated.88 (32%)The more diseases screened, the better.73 (26%)I do not know32 (12%)What do you think about the reasonable application mode of NGS and Tandem Mass Spectrometry (MS/MS) screening?Independent screening mode: both are completely independent, and the results are compared and summarized.61 (22%)It doesn't matter: As two independent methods, they are independent management16 (5.8%)Sequential screening mode: traditional screening is carried out first, and NGS is carried out for suspected positive96 (35%)Unite screening mode: Both test at the same time, summarize the results, and recall for diagnosis39 (14%)I do not know65 (23%)How do you want to improve the above capabilities?Academic conferences and education projects149 (53%)CME online courses32 (11%)Network platform18 (6.5%)Symposium, case discussion, multicenter exchange68 (24%)Othera12 (4.3%)What do you think are the most important technical problems to be solved before the application of NGS?Clear that it is screening technology, not diagnostic technology96 (35%)Current technical conditions are sufficient to meet the clinical needs13 (4.7%)The relationship with traditional screening27 (9.7%)The scope and ability of genetic counseling74 (27%)The screening technology59 (21%)Other (please specify)9 (3.2%)What do you think is the main reason that hinders the promotion of expanded NGS?Healthcare professionals are reluctant to promote because of lack of abilities38 (14%)The cost is too expensive66 (25%)The diseases which are screened can't be effectively treated and intervened66 (25%)The genetic counseling ability and relevant supporting policies cannot be met29 (11%)The technology is not mature and cannot be used for large-scale screening34 (13%)Otherb3 (1.1%)I do not know33 (12%)What do you think is a reasonable price for NGS?AED < 30041 (15%)AED 300–60048 (18%)AED 700–120041 (15%)> AED 12007 (2.6%)Should be covered by insurance132 (49%)a All of the above, some of the above, intensive NGS training workshops, utilizing visual aids/short videos. b Insufficient information about the technology, lack of knowledge of NGS and logistics. Attitudes and perceptions toward NGS among participants (N = 362). a All of the above, some of the above, intensive NGS training workshops, utilizing visual aids/short videos. b Insufficient information about the technology, lack of knowledge of NGS and logistics. Discussion Our study surveyed 362 healthcare professionals in Abu Dhabi to assess their self-reported knowledge, attitudes, and challenges regarding the expansion of gNBS, with 83% having pediatric experience and 58% having worked in newborn screening programs. Self-reported knowledge of gNBS varied, with 46% having good self-reported knowledge and the remaining having limited awareness. Factors associated with higher gNBS self-reported knowledge included working in academia, experience in newborn screening, urban practice settings, and prior experience with TMS. Barriers to gNBS implementation included cost concerns, lack of unified genetic screening guidelines, and ethical/privacy concerns. Most believed gNBS is necessary in Abu Dhabi, while 70% expressed interest in its implementation. The top recommended conditions for expanded gNBS programs were SCID, DMD, and SMA. Key challenges included misinterpretation of genetic information, ethical concerns, and privacy risks. Our findings are broadly consistent with international studies examining healthcare professionals' perspectives on genomic and expanded newborn screening. Similar surveys have reported variable genomic literacy, strong interest in integration, and concerns related to cost, ethical complexity, and workforce preparedness (2, 18, 19). The alignment of our results with these studies suggests that the challenges identified in Abu Dhabi reflect broader global implementation dynamics rather than isolated local barriers. A study by Boland et al. (2) highlights that exposure to gNBS testing and education significantly impacts healthcare professionals' knowledge levels. These findings align with our observation that participants with a higher interest in gNBS or experience in related fields exhibit better knowledge. A recent study by Nurchis et al. (3) supports our findings that professional titles (e.g., interns/residents) are associated with better knowledge, possibly due to more encounters with diagnostic technologies. Furthermore, the UAE's genomic education curricula identified a gap in the coverage of genomic topics at the undergraduate and postgraduate levels (4). The UAE's diverse healthcare workforce, comprising expatriate professionals from various countries, including South Asia, the Middle East, Africa, Europe, and North America, may influence attitudes toward expanded gNBS due to their diverse training backgrounds, genomic technology experiences, and cultural attitudes toward genetic screening (10). This diversity may influence how healthcare professionals perceive ethical concerns, feasibility, and utility of gNBS. Future research should explore how cultural and educational backgrounds influence perceptions and readiness to implement genomic innovations in a diverse healthcare system like the UAE. The analysis of the BabySeq Project's genomic sequencing (20) confirms the association between experience with newborn screening programs and higher gNBS knowledge. Similarly, our study found that prior experience with TMS is associated with better healthcare professional knowledge. Healthcare professionals in our cohort recommended the inclusion of SCID, DMD, and SMA in expanded gNBS programs in the UAE, aligning with local priorities identified by the National Reference Laboratory and with global newborn screening initiatives (11, 13, 21). The prioritization of SCID, SMA, and DMD aligns with established screening principles emphasizing disease severity, early onset, and clinical actionability (22). Early detection of SCID significantly improves survival through timely intervention (23). Similarly, presymptomatic treatment of SMA following newborn screening leads to substantially improved outcomes (24). Although DMD presents additional challenges, long-standing screening experience and evolving therapeutic options support arguments for early identification (25). These findings suggest that healthcare professionals favor inclusion of conditions with clear therapeutic or management benefits. Ethical implications of genetic testing have been extensively studied, with studies showing increased psychological distress (9, 26, 27) and potentially affecting family members due to shared genetic traits (28). Our cohort selected misunderstanding of genetic information, privacy of genetic information, and psychological burden as the main ethical concerns of gNBS. Addressing these challenges requires implementing policies and enhancing literacy, with genetic counselors and Obstetricians-Gynecologists at the forefront in promoting genetic literacy in the community (8, 12, 29). The reasons cited by the healthcare providers in the UAE are their hesitation to expand gNBS due to high costs and a lack of unified genetic targets, as noted in the literature. Nevertheless, in our cohort, the cost was cited as a challenge. However, studies show that sequencing costs are decreasing, making gNBS more feasible (19). On the other hand, healthcare professionals believe that gNBS should include diseases with high penetrance, early treatment, and strong genotype-phenotype correlation. Many genetic diseases do not meet these criteria, complicating the selection of standardized screening panels and introducing technical challenges (19, 21, 30). Despite these challenges, healthcare professionals highlight the benefits of gNBS, including expanding the scope of disease, clarifying ambiguous results, and pinpointing mutations at the molecular level, supported by genomic medicine studies and advancements (9, 11, 26–28). The perception that all newborns (41%) or those with positive MS/MS screening results (33%) should undergo next-generation sequencing (NGS) is consistent with current research and pilot studies. For example, Belgium successfully identified 71 clinical diagnoses in 3,847 newborns using NGS, some of which were overlooked by TMS (8). Moreover, in the USA, GUARDIAN (Genomic Uniform-screening Against Rare Diseases in All Newborns) achieved a screen-positive rate of 3.7% (12). Healthcare professionals prioritize resources for gNBS implementation, including knowledge of neonatal genetic diseases, report interpretation, genetic counseling, policies, regulations, and expert consensus, aligning with global studies and initiatives (5, 14). Our cohort strongly supports capacity building for nurses and midwives to improve their skills in cord blood collection, despite research showing that many nurses lack adequate knowledge, with 86% demonstrating poor knowledge before training interventions (29). Finally, healthcare providers are using academic conferences, online CME courses, collaborative platforms, and case-based learning to enhance their capabilities for gNBS. This aligns with a qualitative study guided by the Action, Actor, Context, Target, and Time framework, with Key informant perspectives on implementing gNBS (19). In this study, educating health professionals was ranked first in the implementation process (stage 0) (19). On the other hand, Chinese multicenter studies steered the importance of case discussions to improve diagnostic accuracy and refine screening panels based on regional disease prevalence (30). This study has several limitations: response bias, lack of exploration of religion, cultural, or psychosocial factors, a broad in-scope survey instrument, and the absence of Likert-scale items may have restricted the ability to measure participant attitudes toward gNBS. Future research should include in-depth interviews or focus groups to capture underlying beliefs and values. Although the sample size (n = 362) met the calculated requirement, the study was conducted in a single Emirate, which may limit generalizability to other regions of the UAE. Additionally, the study may under-represent certain healthcare professionals, especially those in rural areas, due to differences in genomic screening technologies. Implications for policy and practice The findings of this study have short- and long-term implications for genomic newborn screening implementation in the UAE. In the short term, structured training programs, clear national guidelines, and strengthened genetic counseling capacity are essential to address knowledge gaps and ethical concerns identified by healthcare professionals. In the longer term, development of transparent, evidence-based frameworks for condition selection, cost-effectiveness evaluation, and regulatory oversight will be critical to ensure sustainable and equitable integration of genomic newborn screening into routine neonatal care. Engagement of key stakeholders, including policymakers, clinicians, and community representatives, will be important to support responsible expansion efforts. Conclusion This study highlights variability in self-reported genomic knowledge among healthcare professionals in Abu Dhabi and identifies cost, ethical considerations, and guideline development as key perceived challenges to expanding genomic newborn screening. The findings suggest that strengthening training initiatives, clarifying policy frameworks, and enhancing genetic counseling capacity may support future implementation efforts. Further research involving broader stakeholder groups will be important to inform responsible and sustainable expansion of genomic newborn screening in the UAE.